Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET
Agios Pharmaceuticals (Nasdaq: AGIO), a company focused on cellular metabolism and PK activation therapies for rare diseases, will host its second quarter 2025 financial results conference call and webcast on July 31, 2025, at 8:00 a.m. ET.
The presentation will be available through the company's website investor section, with a replay accessible approximately two hours after the event.
Agios Pharmaceuticals (Nasdaq: AGIO), un'azienda specializzata in terapie basate sul metabolismo cellulare e l'attivazione di PK per malattie rare, terrà la sua conferenza telefonica e webcast sui risultati finanziari del secondo trimestre 2025 il 31 luglio 2025 alle 8:00 a.m. ET.
La presentazione sarà disponibile nella sezione investitori del sito web aziendale, con una registrazione riascoltabile circa due ore dopo l'evento.
Agios Pharmaceuticals (Nasdaq: AGIO), una empresa enfocada en terapias de activación de metabolismo celular y PK para enfermedades raras, llevará a cabo su conferencia telefónica y webcast de resultados financieros del segundo trimestre de 2025 el 31 de julio de 2025 a las 8:00 a.m. ET.
La presentación estará disponible en la sección de inversores del sitio web de la compañía, con una repetición accesible aproximadamente dos horas después del evento.
Agios Pharmaceuticals (Nasdaq: AGIO)는 희귀 질환을 위한 세포 대사 및 PK 활성화 치료에 중점을 둔 회사로, 2025년 2분기 재무 실적 컨퍼런스 콜과 웹캐스트를 2025년 7월 31일 오전 8시(동부시간)에 진행할 예정입니다.
발표 자료는 회사 웹사이트 투자자 섹션을 통해 제공되며, 행사 종료 약 2시간 후에 다시보기로도 이용할 수 있습니다.
Agios Pharmaceuticals (Nasdaq : AGIO), une entreprise spécialisée dans les thérapies d'activation du métabolisme cellulaire et PK pour les maladies rares, organisera sa conférence téléphonique et webcast des résultats financiers du deuxième trimestre 2025 le 31 juillet 2025 à 8h00 ET.
La présentation sera accessible via la section investisseurs du site web de la société, avec une rediffusion disponible environ deux heures après l'événement.
Agios Pharmaceuticals (Nasdaq: AGIO), ein Unternehmen, das sich auf zellulären Stoffwechsel und PK-Aktivierungstherapien für seltene Krankheiten spezialisiert hat, wird seine Finanzergebnisse für das zweite Quartal 2025 am 31. Juli 2025 um 8:00 Uhr ET in einer Telefonkonferenz und einem Webcast vorstellen.
Die Präsentation wird im Investor-Bereich der Unternehmenswebsite verfügbar sein, mit einer Wiederholung, die etwa zwei Stunden nach der Veranstaltung abrufbar ist.
- None.
- None.
CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 31, 2025, at 8:00 a.m. ET to report its second quarter 2025 financial results and business highlights.
The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndrome (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
Morgan.Sanford@Agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Eamonn.Nolan@Agios.com
FAQ
When is Agios Pharmaceuticals (AGIO) Q2 2025 earnings call?
How can I access Agios Pharmaceuticals (AGIO) Q2 2025 earnings webcast?
Will there be a replay available for Agios (AGIO) Q2 2025 earnings call?
What does Agios Pharmaceuticals (AGIO) specialize in?
